Navigation Links
Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants

BEVERLY HILLS, Calif., Sept. 4, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company has entered into an agreement with RoxSan Pharmacy Inc. to provide continued specialized compound prescription of Homatropine in a novel oral suspension ("Tropine 3") to support planned FDA compliant Clinical trial participants.  Tropine 3 is a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.  Details regarding the multi-location multi-phase FDA compliant Tropine 3 clinic trials are expected to be finalized within the next few weeks.

"We feel that the RoxSan Pharmacy team and facilities are uniquely qualified to continually supply the Clinical Trial with the highest-quality custom dosage of and support during our planned FDA compliant clinical trials period that is excepted to dramatically increase localized demand," stated Michael Borkowski, CEO and President of Eaton Scientific.

RoxSan Pharmacy has over 40 years of experience with a highly-qualified and educated team of pharmacists, technicians, and chemists to custom prepare high-quality compounded and manufactured medications using several unique delivery systems including, but not limited to, lozenges, nasal spray, cream, lotion, or transdermal gel.  RoxSan Pharmacy services are tilized by a variety of health care participants, including new drug developers, dermatologists, plastic surgeons, orthopedic surgeons, and pain care specialists.

Compounding pharmacies provide medications that are individually formulated to meet the patient's specific health care needs. Custom compounding formulations allows users to quickly and economically modify delivery form, create combination preparations, prescribed specific formulations, and dosage modifications.  Preparation of these specialized products requires chemicals, equipment, and skills that are not available in common pharmacies.

RoxSan Pharmacy is based in Beverly Hills, California and led by the acclaimed doctors Shana Melamed, Pharm.D and son Hootan Melamed, Pharm.D. RoxSan Pharmacy is a member of the Beverly Hills Chamber of Commerce, American Fertility Association, California Pharmacist Association, National Community Pharmacist Association, and the International Academy of Compounding Pharmacies.  Shana Melamed was previously named Beverly Hills Business Woman of The Year in three consecutive years.

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate","estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Eaton Scientific Systems, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
2. Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Womens Health and Drug Sector
3. Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in Menopausal Women
4. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
5. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
6. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
7. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
8. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
9. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
10. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
11. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
Post Your Comments:
(Date:11/24/2015)... 2015 Sectra (STO: SECT B) ... into a multi-year agreement to deploy Breast Imaging ... provide the Breast Center a future-proof platform capable of ... SECT B) announces that Breast Center of Acadiana ... Breast Imaging PACS in its two freestanding imaging centers. This ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... 2015 iRhythm Technologies, Inc. , a leading digital ... that it will participate in the 27th Annual Piper Jaffray Healthcare ... York, NY . Kevin King , Chief Executive ... 2015 at 8:50am ET. --> ... --> . --> iRhythm is a ...
Breaking Medicine Technology:
(Date:11/24/2015)... Peoria, IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and ... dentists who have opened a Koala Center for Sleep Disorders in the US, one of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Bibliomotion is thrilled to ... Me about Reinvention and Diversity by Nancy M. Schlichting, Chief Executive Officer ... failing to adequately address the needs of patients and their families, shaped my desire ...
(Date:11/24/2015)... ... November 24, 2015 , ... World Patent ... Blending, a household invention that revolutionizes the vending machine industry by providing healthy ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... announces Fragrance by Marcelle, a cosmetic invention which offers a combination of natural ... Market in the US is worth $3 billion annually," says Scott Cooper, CEO ...
(Date:11/24/2015)... ... , ... “I am so thrilled, as a newbie here, to leave a mark for the ... School Lounge Makeover® from California Casualty . Stephanie is in her fifth year teaching ... longer tenure. , “This is such an amazing school and we deserve a space where ...
Breaking Medicine News(10 mins):